Orchestra BioMed Holdings, Inc.
Clinical trials sponsored by Orchestra BioMed Holdings, Inc., explained in plain language.
A biomedical company developing therapies for cardiovascular and other diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Pacemaker tweak may lower blood pressure without extra pills Results expected Dec 2026 (estimated) May already have reported ↗
-
Pacemaker tweak may lower blood pressure without extra pills
Disease control Recruiting nowThis study tests a special pacemaker setting designed to lower blood pressure in people with hypertension. About 500 adults who already have or need a pacemaker will take part. The goal is to see if this new setting safely reduces average blood pressure over 24 hours, compared to…
Sponsor: Orchestra BioMed, Inc • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New balloon could offer alternative for clogged heart stents
Disease control Recruiting nowThis study tests a new balloon coated with sirolimus (Virtue SAB) against an existing balloon coated with paclitaxel (AGENT DCB) for treating in-stent restenosis — when a previously placed stent in a heart artery becomes blocked again. About 740 people with one re-narrowed stent …
Sponsor: Orchestra BioMed, Inc • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC